SI-BONE, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Laura A. Francis
- Full Time Employees
- 349
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 471 El Camino Real Santa Clara CA United States of America 95050
- IPO Date
- Oct 17, 2018
- CIK
- 0001459839
- Website
- si-bone.com
- Similar Companies
- Business
- SI-BONE, Inc. is a medical device company specializing in the development and commercialization of proprietary minimally invasive surgical implant systems for the treatment of musculoskeletal disorders of the sacropelvic anatomy. Founded in 2008 and headquartered in Santa Clara, California, the company pioneered the iFuse Implant System® in 2009, a minimally invasive technology designed to fuse the sacroiliac (SI) joint and address SI joint dysfunction associated with chronic lower back pain. SI-BONE's core product portfolio includes the iFuse Implant System® and its advanced versions such as iFuse 3D™, iFuse TORQ®, iFuse TORQ TNT™, and the iFuse Bedrock Granite® Implant System, which extends usage to spinopelvic fixation and adult deformity procedures. The company serves orthopedic surgeons worldwide and supports over 1,400 active physicians with tens of thousands of procedures performed globally. In recent developments, SI-BONE expanded its portfolio by launching the smaller diameter iFuse Bedrock Granite 9.5 mm implant, which received FDA 510(k) clearance and Breakthrough Device Designation in 2024, enhancing the company's position in the billion-dollar market for multi-segment spinal fusion procedures. The Granite 9.5 implant offers improved suitability for patients with smaller anatomies and facilitates placement for complex surgical cases, also achieving a New Technology Add-on Payment from CMS. Additionally, SI-BONE introduced products like iFuse INTRA and the trauma-focused iFuse TORQ TNT in 2024, targeting unmet needs in orthopedic and spine surgery. The company reported robust commercial growth with 2024 revenue reaching $167.2 million, and it continues to anticipate revenue growth in 2025 supported by strong demand, expanded reimbursement, and increased surgical capacity. SI-BONE also obtained FDA Breakthrough Device Designation for a novel implant system for pelvic fracture fixation, reflecting ongoing innovation and expansion into adjacent markets such as pelvic trauma. SI-BONE operates primarily in the medical device industry within the orthopedic and neurosurgery segments, focusing on the diagnosis and treatment of sacroiliac joint disorders, adult spinal deformity, and pelvic trauma. Its operations extend internationally, with a strong commercial presence in the United States and growing adoption worldwide. The company leverages a unique clinical evidence base, including randomized controlled trials and extensive peer-reviewed publications, to support the safety and efficacy of its technologies. This evidence-driven approach underpins SI-BONE’s strategy to maintain leadership in minimally invasive SI joint fusion while broadening its treatment offerings for the spinopelvic anatomical region and complex spine conditions. SI-BONE remains independent and publicly traded under the ticker SIBN. This comprehensive product suite and strategic innovation pipeline positions SI-BONE as a leader in the specialized field of sacropelvic surgical solutions, meeting the needs of surgeons and patients in a historically underserved and under-diagnosed area of orthopedic care. Recent financial and operational trends underscore the company’s disciplined execution and growth trajectory in addressing significant clinical needs with proprietary, minimally invasive surgical technologies.
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
Gazprom Neft says Q1 profit down 3.5% y/y
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SiBone Q1 Earnings Call Highlights
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SiBone (NASDAQ:SIBN) Shares Down 6.8% – What’s Next?
SiBone $SIBN Stake Lowered by JPMorgan Chase & Co.
SiBone (NASDAQ:SIBN) Sets New 52-Week Low – Here’s What Happened
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
Earnings Preview: Si-Bone (SIBN) Q4 Earnings Expected to Decline